Variable | Frequency |
Median (age yrs) | 52 |
Sex Male Female |
17 13 |
Hypertensive before study Normotensive before study | 7 23 |
No of metastatic sites 1 >1 |
21 9 |
Performance status 0 1 2 3 |
14 12 3 1 |
FOLFOX chemotherapy CapeOX chemotherapy | 21 9 |
Median no of cycles of Bevacizumab | 9 |
Antihypertensive treatment before start of bevacizumab (n = 7) Calcium channel blockers Angiotensin Converting enzyme inhibitor Beta blockers Combination |
3 1 1 2 |
Family history of hypertension Yes No |
5 25 |
Primary tumour Colon Recto sigmoid Rectum |
20 2 8 |
Metastatic site Liver alone Lung alone Bone alone Multiple |
17 2 2 9 |
CEA (ng/ml) <10 >10 |
3 27 |